Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study

The Lancet Oncology
Howard A BurrisOwen A O'Connor

Abstract

Umbralisib (TGR-1202) is a novel next-generation inhibitor of phosphatidylinositol 3-kinase (PI3K) isoform p110δ (PI3Kδ), which is structurally distinct from other PI3Kδ inhibitors and shows improved isoform selectivity. Umbralisib also uniquely inhibits casein kinase-1ε, a major regulator of protein translation. The aim of this first-in-human phase 1 study was to establish the safety and preliminary activity profile of umbralisib in patients with haematological malignancies. We did an open-label, phase 1, dose-escalation study at seven clinics in the USA. We recruited patients aged at least 18 years with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma, B-cell and T-cell non-Hodgkin lymphoma, or Hodgkin's lymphoma, who had received one or more previous lines of therapy, with measurable and assessable disease, and adequate organ system function. Patients self-administered an umbralisib oral tablet once per day in 28-day cycles, with dose escalation done in a traditional 3 + 3 design to establish safety and determine the maximum tolerated dose. In initial cohorts, patients took umbralisib in a fasting state at a starting dose of 50 mg, increasing to 100, 200, 400, 800, 1200, and 1800 mg until th...Continue Reading

Citations

May 17, 2018·Leukemia & Lymphoma·Christopher PleyerClare Sun
Jun 2, 2018·Expert Opinion on Investigational Drugs·Kelly VallaJean L Koff
Feb 1, 2019·Blood·Carla Casulo, Paul M Barr
Dec 7, 2018·Hematology·Jennifer R Brown
May 30, 2019·Future Oncology·Anna M FrustaciMarco Montillo
Apr 26, 2019·Leukemia & Lymphoma·Tadeusz RobakMartin Dreyling
Sep 27, 2019·Blood·Krish PatelJohn M Pagel
Nov 2, 2019·Expert Opinion on Therapeutic Patents·Yifan FengMinhang Xin
Nov 26, 2019·The Cancer Journal·Jennifer R Brown
Oct 9, 2019·Current Opinion in Oncology·Luana SchiattoneLydia Scarfò
Apr 6, 2019·Anti-cancer Agents in Medicinal Chemistry·Aimen K AljoundiMahmoud E S Soliman
Mar 13, 2020·Expert Opinion on Pharmacotherapy·Dirk L Kienle, Stephan Stilgenbauer
Apr 16, 2020·Expert Opinion on Pharmacotherapy·Anna Maria FrustaciMarco Montillo
Feb 19, 2020·Expert Opinion on Pharmacotherapy·Taha Al-JuhaishiVictor Yazbeck
Jun 25, 2020·Expert Review of Clinical Pharmacology·Massimo MagagnoliArmando Santoro
Jan 7, 2020·Current Topics in Medicinal Chemistry·Rammohan R Y Bheemanaboina
Jul 28, 2020·Expert Opinion on Drug Safety·Shinichi MakitaKensei Tobinai
Aug 11, 2020·American Journal of Hematology·Ludovic JondrevilleFlorence Nguyen-Khac
Jul 14, 2020·Future Oncology·Mayur Narkhede, Bruce D Cheson
May 15, 2020·Expert Opinion on Investigational Drugs·Elżbieta Iskierka-Jażdżewska, Tadeusz Robak
Dec 12, 2018·Current Hematologic Malignancy Reports·Maliha Khan, Tanya Siddiqi
Jun 17, 2019·Current Hematologic Malignancy Reports·Krish Patel, John M Pagel
Jun 8, 2019·British Journal of Haematology·Carla Casulo
Nov 15, 2019·HemaSphere·Deyan Y YosifovDaniel Mertens
May 29, 2018·Current Treatment Options in Oncology·Thomas D Rodgers, Paul M Barr
Aug 17, 2018·Current Hematologic Malignancy Reports·Joanna Rhodes, Daniel J Landsburg
Nov 22, 2019·Expert Review of Hematology·Elżbieta Iskierka-Jażdżewska, Tadeusz Robak
Nov 15, 2019·HemaSphere·Kai HübelMartin Dreyling
Jul 31, 2019·Current Hematologic Malignancy Reports·Gottfried von Keudell, Alison J Moskowitz
Sep 12, 2018·Expert Opinion on Pharmacotherapy·Hamza HashmiFarrukh T Awan
May 10, 2020·HemaSphere·Kai HübelAjay K Gopal
Nov 30, 2019·Hematological Oncology·Francesco PiazzaGianpietro Semenzato
May 2, 2020·Current Treatment Options in Oncology·Vladimir Sapon-CousineauSarit Assouline
Dec 17, 2019·Therapeutic Advances in Hematology·Marisa J L AitkenSean M Post
Jul 9, 2020·Scandinavian Journal of Immunology·Sigrid S SkånlandKjetil Taskén
Oct 21, 2020·Leukemia & Lymphoma·Aswin Sekar, Matthew S Davids
Nov 3, 2020·Leukemia & Lymphoma·Philipp Berning, Georg Lenz
Nov 3, 2020·Clinical Lymphoma, Myeloma & Leukemia·Tycel J PhillipsVincent Ribrag

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.